Trial Profile
A Two-arm, Randomised, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36 Week Treatment Course
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Atacicept (Primary)
- Indications Optic neuritis
- Focus Therapeutic Use
- Acronyms ATON
- Sponsors EMD Serono
- 25 Sep 2014 New trial record